These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 33766261)
1. Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease. Maas R; Rodionov RN J Am Coll Cardiol; 2021 Mar; 77(12):1551-1553. PubMed ID: 33766261 [No Abstract] [Full Text] [Related]
2. Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. Reddy R; Diaz P; Ramasamy R Eur Urol; 2022 Jan; 81(1):120-121. PubMed ID: 34772548 [No Abstract] [Full Text] [Related]
3. Phosphodiesterase-5 Inhibitors in Men With Stable Coronary Artery Disease. Wen Z; Feng Y; Jiang L J Am Coll Cardiol; 2021 Jul; 78(3):294-295. PubMed ID: 34266584 [No Abstract] [Full Text] [Related]
4. Erectile dysfunction in the cardiac patient. Kloner RA Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500 [TBL] [Abstract][Full Text] [Related]
5. [Optimization of the use of phosphodiesterase-5 inhibitors]. Pushkar' DIu; Segal AS Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030 [No Abstract] [Full Text] [Related]
6. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Raina R; Lakin MM; Agarwal A; Sharma R; Goyal KK; Montague DK; Klein E; Zippe CD Urology; 2003 Jul; 62(1):110-5. PubMed ID: 12837433 [TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of erectile dysfunction--what is still needed today?]. Weiske WH Urologe A; 2003 Oct; 42(10):1317-21. PubMed ID: 14569379 [TBL] [Abstract][Full Text] [Related]
8. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. Mason RG J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189 [No Abstract] [Full Text] [Related]
9. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction". Kloner RA; Montorsi P; DeBusk RF J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835 [No Abstract] [Full Text] [Related]
10. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future]. Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532 [TBL] [Abstract][Full Text] [Related]
11. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Carson CC Curr Urol Rep; 2003 Dec; 4(6):488-96. PubMed ID: 14622503 [TBL] [Abstract][Full Text] [Related]
12. [Current role of sildenafil in the management of erectile dysfunction]. Akhvlediani ND; Matyukhov IP Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Kuthe A Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Corbin JD; Francis SH; Webb DJ Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329 [TBL] [Abstract][Full Text] [Related]